LifeMD LFMD 深 滬
等待開盤 09-25 09:30:00 美东时间
2.90
-0.150
-4.92%
華盛通- 最 高3.06
- 今 開3.04
- 成交量 58.81万股
- 最 低 2.90
- 昨 收 3.05
- 總市值 1.40亿
- 52周最高 7.12
- 市盈率 靜 --
- 換手率 1.22%
- 52周最低 2.56
- 委 比 -28.59%
- 總股本 4820.08万
- 歷史最高 33.02
- 量 比 0.89
- 振 幅 5.25%
- 歷史最低 1.14
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多LifeMD, Inc. 8.875% CUM PFD A declares $0.5547 dividend
LifeMD, Inc. 8.875% CUM PFD A (LFMDP) declares $0.5547/share quarterly dividend, in line with previous. Forward yield 9.5% Payable Oct. 15; for shareholders of record Oct. 2; ex-div Oct. 2. See LFMDP ...
09-23 16:18
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
HC Wainwright & Co. Reiterates Buy on LifeMD, Maintains $9 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates LifeMD (NASDAQ:LFMD) with a Buy and maintains $9 price target.
09-17 23:49
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
BTIG Maintains Buy on LifeMD, Lowers Price Target to $9
BTIG analyst David Larsen maintains LifeMD (NASDAQ:LFMD) with a Buy and lowers the price target from $10 to $9.
08-06 17:28
LifeMD shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 sales guidance. Also, the company issued Q3 sales guidance below estimates.
LifeMD shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 sales guidance. Also, the company issued Q3 sales guidance below estimates.
08-06 05:21
LifeMD Lowers FY2026 Sales Guidance from $220.000M-$230.000M to $205.500M-$212.500M vs $222.046M Est
LifeMD (NASDAQ:LFMD) lowers FY2026 sales outlook from $220.000 million-$230.000 million to $205.500 million-$212.500 million vs $222.046 million estimate.
08-06 04:49
LifeMD Q2 EPS $(0.16) Misses $(0.15) Estimate, Sales $47.300M Miss $49.152M Estimate
LifeMD (NASDAQ:LFMD) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 166.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $47.300 million which...
08-06 04:13
LifeMD 2026年第二季度财报：品牌GLP-1转型拖累营收与盈利
LifeMD 2026年第二季度营收4,728万美元，同比下降约3.5%；毛利率升至约89%，但调整后EBITDA亏损353万美元，公司同步下调全年营收与盈利指引。
08-06 00:02
